ARGX
Healthcareargenx SE · Biotechnology · $50B
What is argenx SE?
argenx SE is a global biotechnology company focused on developing antibody-based therapies for severe autoimmune diseases. Headquartered in Amsterdam, the company has built a growing commercial presence across the United States, Europe, Japan, and beyond.
argenx generates revenue primarily through its commercialized therapies targeting the FcRn pathway — a mechanism that regulates antibody levels in the body. Its lead asset, efgartigimod, is approved and marketed under the VYVGART and VYVGART HYTRULO brands for multiple autoimmune indications. The company also advances a deep pipeline of early- and late-stage candidates targeting a range of rare and debilitating immune-mediated conditions, supported by strategic partnerships with AbbVie, Zai Lab, and LEO Pharma.
argenx was founded in 2017 and is headquartered in Amsterdam, Netherlands.
- VYVGART and VYVGART HYTRULO — approved efgartigimod therapies for autoimmune diseases
- Empasiprubart — pipeline candidate for multifocal motor neuropathy and related conditions
- ARGX-119 — early-stage program targeting congenital myasthenic syndrome and ALS
- ENHANZE SC — subcutaneous drug delivery platform
- Broad pipeline across FcRn, IL-6, and immune system targets
Is ARGX a Good Stock to Buy?
UQS Score rates ARGX as Very Good overall, reflecting a differentiated biotech with meaningful commercial traction.
The Growth pillar stands out as one of the strongest signals in argenx's profile, consistent with a company expanding its approved indications and geographic reach. The Risk pillar also rates favorably, suggesting the company's financial structure and operational profile compare well within the biotech sector.
The Valuation pillar is rated Elevated, meaning the market has priced in a significant amount of future success — a common dynamic for high-growth biotechs with expanding pipelines. The Moat pillar is Neutral, reflecting the competitive nature of the autoimmune therapy landscape.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ARGX pay dividends?
No — argenx SE does not currently pay a dividend.
argenx does not currently pay a dividend. This is typical for clinical-stage and growth-oriented biotechs, where capital is directed toward pipeline development, clinical trials, and commercial expansion rather than shareholder distributions. Investors in ARGX are generally seeking long-term value creation through drug approvals and revenue growth rather than income.
When does ARGX report earnings?
argenx reports earnings on a quarterly cadence, consistent with standard practice for US-listed and dual-listed equities.
The company's recent reporting periods have reflected its transition from a pipeline-stage biotech to a commercial-stage business, with growing product revenues from its approved therapies. Investors typically focus on net product sales, pipeline milestones, and cash runway when evaluating each quarter's results.
For the most recent quarter's results and upcoming reporting dates, visit argenx's official investor relations page.
ARGX Price History
+188.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in argenx SE?
Based on argenx SE's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ARGX Long-term Outlook
argenx's Strong Growth pillar points to a company with meaningful near-term revenue expansion potential, driven by label expansions for efgartigimod and new indication approvals. The Strong Risk rating suggests the company is navigating its growth phase with a relatively stable financial footing. However, the Elevated Valuation pillar is a reminder that much of this optimism is already reflected in the share price, leaving limited margin for execution missteps.
Growth drivers
- Expanding approved indications for efgartigimod across multiple autoimmune diseases
- Geographic expansion into Japan, China, and additional international markets
- Pipeline advancement of empasiprubart and other late-stage candidates
Key risks
- Elevated valuation leaves little room for clinical or commercial disappointments
- Competitive pressure from established immunology players in overlapping indications
- Pipeline execution risk across a broad and complex clinical program
ARGX vs Peers
argenx operates in a competitive rare disease and autoimmune therapy landscape alongside several well-capitalized biotechs.
Alnylam focuses on RNA interference therapeutics for rare genetic diseases, a distinct mechanism from argenx's antibody-based FcRn approach.
Regeneron is a larger, more diversified biopharmaceutical company with a broad immunology and oncology portfolio, giving it greater commercial scale than argenx.
Insmed specializes in rare pulmonary diseases, competing with argenx for rare disease patient populations and specialist physician attention.
Frequently Asked Questions
What does argenx do?
argenx is a biotechnology company that develops antibody-based therapies for severe autoimmune diseases. Its lead commercial products, VYVGART and VYVGART HYTRULO, are approved for multiple indications including myasthenia gravis. The company also maintains a broad pipeline targeting rare immune-mediated conditions across multiple therapeutic areas.
Does ARGX pay dividends?
argenx does not currently pay a dividend. As a growth-stage biotech, the company reinvests its capital into clinical development and commercial expansion. Investors in ARGX are typically focused on long-term capital appreciation rather than dividend income.
When does ARGX report earnings?
argenx reports financial results on a quarterly cadence. Specific upcoming earnings dates are not covered by our data source — check argenx's investor relations page or your brokerage platform for the most current schedule.
Is ARGX a good stock to buy?
UQS Score rates ARGX as Very Good, with particularly strong signals in the Growth and Risk pillars. The Valuation pillar is rated Elevated, which means the stock may already reflect significant future expectations. Whether it suits your portfolio depends on your risk tolerance and investment horizon. View the full pillar breakdown on UQS Pro.
Is ARGX overvalued?
The UQS Valuation pillar for ARGX is rated Elevated, indicating the market is pricing in substantial future growth. This is common for high-growth biotechs with expanding commercial pipelines. Investors should weigh this against the company's Strong Growth profile when forming their own view.
How does ARGX compare to its competitors?
argenx competes in the rare disease and autoimmune space alongside companies like Regeneron, Alnylam, and Insmed. Each pursues different mechanisms and indications — argenx's FcRn-targeting approach is relatively differentiated. The UQS platform provides a side-by-side quality score comparison for Pro members.
What is ARGX's market cap bracket?
argenx is classified as a large-cap company, reflecting its established commercial revenues and significant market recognition within the global biotech sector.
Who founded argenx?
argenx was incorporated in 2017, though its scientific roots trace back to earlier research collaborations in Belgium and the Netherlands. Founding and leadership history is publicly available on argenx's corporate website and in its regulatory filings.
Is ARGX a long-term quality investment?
From a quality indicator perspective, ARGX's Very Good UQS Score — anchored by Strong Growth and Strong Risk ratings — suggests a company with meaningful long-term potential. The Elevated Valuation pillar is worth monitoring, as entry price matters for long-term outcomes. The complete analysis is available to UQS Pro members.
What is the main competitive advantage of argenx?
argenx's core differentiation lies in its proprietary FcRn-targeting platform, which underpins efgartigimod and several pipeline candidates. This mechanism allows the company to pursue multiple autoimmune indications from a single scientific foundation, supported by partnerships with AbbVie, Zai Lab, and LEO Pharma for broader reach.
What sector does ARGX belong to?
argenx operates in the Healthcare sector, specifically within the biotechnology industry. It focuses on rare and severe autoimmune diseases, a segment characterized by high unmet medical need and strong pricing power for approved therapies.
Is ARGX a growth stock or value stock?
Based on its UQS pillar profile, ARGX leans firmly toward growth. The Growth pillar is rated Strong, while the Valuation pillar is Elevated — a combination typical of growth-oriented biotechs where investors pay a premium for future revenue expansion rather than current earnings.
Unlock Full ARGX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for ARGX
- ✓Access detailed financial metrics and quality indicators
- ✓Compare ARGX side-by-side with biotech peers
- ✓Screen for top-rated Healthcare stocks by pillar
- ✓Get the full analyst-style quality view in one place
Pro Analysis
ARGX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 72.0 | 69.8 | 55.0 | 100.0 | 100.0 | 38.8 | +0.1 |
| May 22, 2026 | 71.9 | 69.8 | 55.0 | 100.0 | 100.0 | 38.4 | -0.1 |
| May 21, 2026 | 72.0 | 69.8 | 55.0 | 100.0 | 100.0 | 38.9 | -0.1 |
| May 20, 2026 | 72.1 | 69.8 | 55.0 | 100.0 | 100.0 | 39.3 | -0.1 |
| May 19, 2026 | 72.2 | 69.7 | 55.0 | 100.0 | 100.0 | 40.5 | +0.1 |
| May 16, 2026 | 72.1 | 69.7 | 55.0 | 100.0 | 100.0 | 39.2 | +0.2 |
| May 15, 2026 | 71.9 | 69.7 | 55.0 | 100.0 | 100.0 | 38.3 | -0.1 |
| May 14, 2026 | 72.0 | 69.7 | 55.0 | 100.0 | 100.0 | 39.1 | 0.0 |
| May 12, 2026 | 72.0 | 69.7 | 55.0 | 100.0 | 100.0 | 38.5 | -0.2 |
| May 11, 2026 | 72.2 | 69.8 | 55.0 | 100.0 | 100.0 | 40.2 | -0.3 |
ARGX — Pillar Breakdown
Quality
— 69.8/100 (25%)argenx SE shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)argenx SE is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 100.0/100 (15%)argenx SE carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 38.8/100 (15%)argenx SE has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 55/100 (25%)argenx SE has meaningful competitive advantages that should protect its market position. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ARGX.
Score Composition
Financial Data
More Stock Analysis
How is the ARGX UQS Score Calculated?
The UQS (Unified Quality Score) for argenx SE is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses argenx SE's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether argenx SE is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.